General Health

Lionheart Acquisition Corporation II Shareholders Approve Previously Announced Business Combination with MSP Recovery

Retrieved on: 
Wednesday, May 18, 2022 - 8:32pm

Lionheart Acquisition Corporation II (Nasdaq: LCAPU, LCAP, LCAPW, Lionheart or LCAP), a publicly traded special purpose acquisition company, today announced that shareholders of record as of April 18, 2022 approved the previously announced business combination (the Business Combination) with MSP Recovery, LLC (MSP Recovery or MSP) a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader.

Key Points: 
  • Lionheart Acquisition Corporation II (Nasdaq: LCAPU, LCAP, LCAPW, Lionheart or LCAP), a publicly traded special purpose acquisition company, today announced that shareholders of record as of April 18, 2022 approved the previously announced business combination (the Business Combination) with MSP Recovery, LLC (MSP Recovery or MSP) a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader.
  • Pursuant to the Business Combination, at the closing, MSP will combine with LCAP and the combined companys name will be MSP Recovery, Inc.
  • MSP Recovery provides the healthcare industry with comprehensive compliance solutions, while innovating technologies to help save lives.
  • For more information, visit: www.msprecovery.com
    Lionheart Acquisition Corporation II is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

neuro42 Licenses Robot from Johns Hopkins University

Retrieved on: 
Wednesday, May 18, 2022 - 11:28pm

neuro42, Inc. (neuro42 or the Company), a medical imaging, robotics, and AI technology company, today announced an exclusive licensing agreement with Johns Hopkins University (Johns Hopkins) for their MR compatible robot for head, neck and spine applications, with additional non-exclusive licenses for related technologies and patents.

Key Points: 
  • neuro42, Inc. (neuro42 or the Company), a medical imaging, robotics, and AI technology company, today announced an exclusive licensing agreement with Johns Hopkins University (Johns Hopkins) for their MR compatible robot for head, neck and spine applications, with additional non-exclusive licenses for related technologies and patents.
  • Developed by Dr. Dan Stoianovici, director of the Urology Robotics Program at the Brady Urological Institute and a professor of neurosurgery at the Johns Hopkins University School of Medicine, the robot provides targeted needle insertion with precision depth control.
  • We look forward to collaborating with the team at Johns Hopkins to enable safe and effective intraoperative MR treatments using the neuro42 scanner and the robot, said Abhita Batra, Co-founder and Chief Strategy Officer of neuro42.
  • neuro42, Inc. is a San Francisco, CA based medical technology company focused on diagnostic imaging and image guided surgical interventions of the brain.

Gelesis to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 18, 2022 - 9:05pm

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220518006013/en/
    Wednesday, May 25, 2022: UBS Global Healthcare Conference: Gelesis will host a presentation beginning at 8:30 a.m. Eastern Time.
  • The presentation will be webcast live here and on the Companys investor relations website at ir.gelesis.com .
  • Wednesday, June 1, 2022: Third Annual Loop Capital Conference: Gelesis will participate virtually.
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis) is a consumer-centered biotherapeutics company and the maker of Plenity, which is inspired by nature and FDA cleared to aid in weight management.

CHD Files Comments with FCC Urging Accommodation of Millions of People Sickened by Wireless Radiation

Retrieved on: 
Wednesday, May 18, 2022 - 6:27pm

The proceeding was required by the Infrastructure Investment and Jobs Act (Infrastructure Act) and President Bidens Executive Order 13985 .

Key Points: 
  • The proceeding was required by the Infrastructure Investment and Jobs Act (Infrastructure Act) and President Bidens Executive Order 13985 .
  • CHD is calling for, as a matter of right, access to wired (fiber-based) broadband to the premises for the EMS disabled.
  • These individuals simply cannot be around RF (wireless) Radiation because it makes them sick , said CHD president and general counsel Mary Holland.
  • CHDs comments were accompanied by a white paper written by Susan Foster and Odette J. Wilkins , Eliminating Digital Discrimination for the EMS Disabled.

Global Osteoporosis Drugs Market Report (2022 to 2027) - Featuring GlaxoSmithKline, Novartis International and Merck & Co Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 6:00pm

The global osteoporosis drugs market is projected to reach $16.43 Billion in 2027, from $12.01 Billion in 2021.

Key Points: 
  • The global osteoporosis drugs market is projected to reach $16.43 Billion in 2027, from $12.01 Billion in 2021.
  • Remarkably, as there is no cure for osteoporosis, FDA has approved drugs to prevent, slow, or stop osteoporosis progress.
  • Globally, Osteoporosis Drugs Market is primarily driven by a significant rise in the prevalence of osteoporosis disorder.
  • Moreover, the senior population globally possessing high susceptibility for osteoporosis is further presumed to boost the high demand for Osteoporosis Drugs.

United States Respiratory Protective Equipment Market Report 2022: Air-purifying Respirators & Supplied Air Respirators - Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 4:41pm

The "United States Respiratory Protective Equipment Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Respiratory Protective Equipment Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The companies and dealers/distributors profiled in the report include manufacturers & suppliers of respiratory protective equipment market in the United States.
  • The report provides detailed insights into:
    The report answers questions such as:
    What is the market size of respiratory protective equipment market in the United States?
  • The report on the United States respiratory protective equipment market provides a detailed analysis of segments in the market based on product type, and end-use industry.

United States Plastic Surgery Market Analysis/Forecast Report 2022-2027: Focus on Aesthetic Surgery, Burn Surgery, Craniofacial Surgery, Hand Surgery, Microsurgery, & Pediatric Plastic Surgery - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 4:16pm

The "United States Plastic Surgery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Plastic Surgery Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The companies and dealers/distributors profiled in the report include manufacturers & suppliers of plastic surgery market in the United States.
  • The report provides detailed insights into:
    The report answers questions such as:
    What is the market size of plastic surgery market in the United States?
  • What are the modes of entering the United States plastic surgery market?

Global Lateral Flow Assays Market Analysis Report 2022: Amid the COVID-19 Crisis, the Market is Projected to Reach a Revised Size of $11.2 Billion by 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022 - 3:59pm

Amid the COVID-19 crisis, the global market for Lateral Flow Assays estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$11.2 Billion by 2026, growing at a CAGR of 5.9% over the analysis period.

Key Points: 
  • Amid the COVID-19 crisis, the global market for Lateral Flow Assays estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$11.2 Billion by 2026, growing at a CAGR of 5.9% over the analysis period.
  • Lateral flow assays are assays designed to effectively identify compounds of interest present in complex mixtures within 5-30 minutes.
  • Another factor bolstering the market growth is continuing technological advancements associated with lateral flow assays.
  • The COVID-19 pandemic has presented an ideal growth opportunity for lateral flow assays due to robust demand for lateral flow assay-based screening tests.

Voices Urging Action on Antimicrobial Resistance Take to Capitol Hill

Retrieved on: 
Wednesday, May 18, 2022 - 4:43pm

Today the Partnership to Fight Infectious Disease (PFID) , along with the Infectious Diseases Society of America (IDSA), Boomer Esiason Foundation and the Cystic Fibrosis Foundation, unite to highlight the urgency for action on antimicrobial resistance (AMR).

Key Points: 
  • Today the Partnership to Fight Infectious Disease (PFID) , along with the Infectious Diseases Society of America (IDSA), Boomer Esiason Foundation and the Cystic Fibrosis Foundation, unite to highlight the urgency for action on antimicrobial resistance (AMR).
  • An estimated 2.8 million antibiotic-resistant infections occur in the U.S. each year and more than 35,000 people die as a result.
  • "The world is full of urgent threats, but we can take this one off the table with bold action now.
  • Her story as told in Salt in My Soul underscores the urgent need to develop new and more effective treatments.

Wyoming Board of Pharmacy Leverages Bamboo Health’s Solution to Deliver Its Prescription Drug Monitoring Program

Retrieved on: 
Wednesday, May 18, 2022 - 3:01pm

Bamboo Health , formerly Appriss Health and PatientPing, a healthcare technology solutions company focused on fostering care collaboration and providing information and actionable insights across the entire continuum of care, today announced its partnership with the Wyoming Board of Pharmacy to deliver a solution for its Prescription Drug Monitoring Program (PDMP) effective June 29.

Key Points: 
  • Bamboo Health , formerly Appriss Health and PatientPing, a healthcare technology solutions company focused on fostering care collaboration and providing information and actionable insights across the entire continuum of care, today announced its partnership with the Wyoming Board of Pharmacy to deliver a solution for its Prescription Drug Monitoring Program (PDMP) effective June 29.
  • Through its contract with Wyoming Board of Pharmacy, providers and dispensers across the state of Wyoming will now have access to PDMP data through Bamboo Healths PMP AWARxE solution, allowing visibility into their patients controlled substance use.
  • As the states board of pharmacy, were excited to transition to Bamboo Healths PDMP solution this summer.
  • Health systems, payers, providers, pharmacies, governments, individuals, and other organizations rely on Bamboo Health to improve care and reduce cost.